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Abstract
STAT6 transcription factor has become a potential molecule for therapeutic intervention because it regulates broad range of
cellular processes in a large variety of cell types. Although some target genes and interacting partners of STAT6 have been
identified, its exact mechanism of action needs to be elucidated. In this study, we sought to further characterize the
molecular interactions, networks, and functions of STAT6 by profiling the mRNA expression of STAT6 silenced human lung
cells (NCI-H460) using microarrays. Our analysis revealed 273 differentially expressed genes after STAT6 silencing. Analysis of
the gene expression data with Ingenuity Pathway Analysis (IPA) software revealed Gene expression, Cell death, Lipid
metabolism as the functions associated with highest rated network. Cholesterol biosynthesis was among the most enriched
pathways in IPA as well as in PANTHER analysis. These results have been validated by real-time PCR and cholesterol assay
using scrambled siRNA as a negative control. Similar findings were also observed with human type II pulmonary alveolar
epithelial cells, A549. In the present study we have, for the first time, shown the inverse relationship of STAT6 with the
cholesterol biosynthesis in lung cancer cells. The present findings are potentially significant to advance the understanding
and design of therapeutics for the pathological conditions where both STAT6 and cholesterol biosynthesis are implicated
viz. asthma, atherosclerosis etc.
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Introduction
STAT6 is one of the seven members of the family of trans-
cription factors that participate in the regulation of gene ex-
pression when cells encounter various extracellular polypeptides
like cytokines, hormones and growth factors and regulate a broad
range of cellular processes including proliferation, differentiation
and apoptosis [1,2,3,4]. In general, unphosphorylated STAT
proteins exist as latent forms in the cytoplasm. The cytokine ex-
posure leads to STAT phosphorylation by Janus kinases and once
phosphorylated the dimerization of individual STAT proteins
occur via their SH2 domains followed by migration of functional
STAT dimer to the nucleus where it can bind DNA and directly
activate transcription of cytokine responsive genes [5,6]. Just like
the other members of the STAT family, STAT6 plays a dual role
of signal transducer and activator of transcription by either directly
regulating gene expression or by interacting with a wide variety of
other transcription factors [7].
IL-4 and IL-13 induced STAT6 signaling has been shown to
play an important role in the differentiation of Th2 cells, B cell
induced expression of IgG and IgE and the cell surface display of
MHC class II and CD23 [8,9,10,11]. Though STAT6 is primarily
known to be associated with allergic inflammation and asthma,
STAT6 deregulation has also been implicated in various other
diseases. STAT6 plays a key role in T cell hepatitis via enhancing
expression of eotaxins in hepatocytes and endothelial cells, and
induces IL-5 expression, infiltration of eosinophils and neutrophils
into the liver and leading to hepatitis [12]. There are also
evidences that IL-4-induced activation of STAT6 is associated
with reduced hepatic expression of TNFa as well as attenuation of
liver neutrophil recruitment and may protect against hepatic
ischemia/reperfusion injury [13]. STAT6 has also been demon-
strated to be involved in ciliary mechanosensation in kidney
epithelial cell [14]. Recently, IL-4 and STAT6 gene polymor-
phisms have also been found associated with systemic lupus
erythematosus development in Chinese patients [15]. Shum et al
in 2006 provided a link between allergic inflammation and fatty
acid metabolism where they have shown that an IL-4/STAT6
regulated gene aP2, which plays an important role in lipid
metabolism, is required in Th2 mediated allergic airway
inflammation [16] and recently STAT6 has been found to play
a role in regulating lipid homeostasis in liver as increased lipid
deposition was observed in STAT6 knockout mice [17]. In
addition to the above findings, Zhang et al in 2006 reported that
STAT6 silencing inhibits proliferation and induces apoptosis in
colon cancer HT-29 cells [4]. In another study, Das et al in 2007
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human prostate cancer [18]. This effect of STAT6 was further
strengthened in a study by Cui et al in 2007, where they have
shown that unphosphorylated STAT6 transcriptionally up regu-
lates COX-2 expression and protects against apoptosis in NSCLC
(non-small cell lung cancer) cells [19].
Although, a few target genes and some interacting partners of
STAT6 have been known till date, the precise mechanisms of
STAT6 mediated signaling is largely unknown. In view of this, we
sought to study the effect of STAT6 silencing on genome wide
gene expression patterns in NCI-H460 cells (lung cancer
epithelial). The results obtained after siRNA mediated silencing
of STAT6 in NCI-H460 cells were also validated in A549 cells.
Materials and Methods
Cell culture and siRNA Transfection
Lung carcinoma (NCI-H460 and A549) cells were obtained from
National Centre for Cell Science, Pune, India and maintained in
RPMI-1640/DMEM media, containing 10% fetal calf serum and
antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin) at 37uC
in a humidified atmosphere of 5% CO2 in air.
For transfection in 12 well plates, 1.2610
5 cells were seeded per
well and allowed to adhere overnight. The following day cells were
transfected with 60 nM of validated siRNA (Ambion, USA) using
4 ml of lipofectamine 2000 (Invitrogen, USA) according to the
manufacturer’s protocol. Wherever indicated, cells were stimulat-
ed with 50 ng/ml recombinant human IL-4 (BD Pharmingen,
USA) for 4 h. The cells were harvested after 24 h/48 h/72h post
transfection and used for the experiments. The untransfected and
scrambled siRNA transfected cells were harvested after 48 h for all
the experiments unless otherwise indicated.
RNA Extraction and Real Time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, CA,
USA) and 2 mg of RNA was reverse transcribed using Rever-
tAid
TM H Minus Reverse Transcriptase kit (Fermentas, USA)
according to the manufacturer’s protocol. Real time PCR was
done using SYBR Green PCR master mix (Applied Biosystems,
Foster City, CA). Results were normalized with 18s rRNA. Data
was analysed using Pfaffl’s method [20]. The primer sequences
used for RT-PCR are given in Table S1.
Western Blotting
Cells were trypsinized and cell pellets were lysed with modified
RIPA buffer {50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP40, 0.25% Na deoxycholate, 1 mg/ml aprotinin,
1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), 1 mM sodium orthovandate, and 1mM
sodium fluoride} and kept in ice for 30 min. Lysate was
centrifuged at 12000 rpm for 30 min, supernatant collected and
protein estimation was done using the BCA method. Equal
amounts of protein (50 mg) were separated on 12% sodium
dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membrane. The membrane
was blocked with 3% skim milk in Tris buffered saline (20 mM
Tris, 150 mM NaCl, pH 7.4) with 0.1% Tween-20 for 1 h and
then incubated with primary antibody in 1% skim milk for 2 h
followed by incubation with appropriate secondary antibody (anti-
mouse ALP linked or/anti-rabbit ALP linked) for 1 h. Blots were
developed using NBT- BCIP as substrate. Equal loading of protein
was confirmed using GAPDH antibody. Measurement of signal
intensity on PVDF membranes after western blotting was
performed using AlphaImager 3400 (Alpha InnoTech Corpora-
tion, San Leandro, California). The IDV values are calculated as
the density values of the specific protein band/GAPDH density
values. The fold change with respect to untransfected cells was
then calculated based on IDV values. All experiments were
repeated at least three times; representative results are presented.
Illumina Microarray
Genome wide effect of STAT6 silencing was studied using
Illumina microarray. Two biological replicates of untransfected
NCI-H460 cells and NCI-H460 cells transfected with 60nM of
STAT6 siRNA (for 48 h) were used in the array experiment. Total
RNA was extracted using Trizol reagent (Invitrogen, CA, USA),
purified and concentrated using RNeasy MinElute Cleanup Kit
(Qiagen, CA, USA) as per the manufacturer’s protocol. All RNA
samples were tested for integrity by gel electrophoresis. The
Illumina TotalPrep RNA Amplification Kit (Ambion, TX, USA)
was used to generate biotinylated, amplified RNA. In brief, 500 ng
of total RNA was reverse transcribed with an oligo(dT) primer
using ArrayScript enzyme and amplified overnight with T7 RNA
polymerase and labeled with biotin according to the manufactur-
er’s protocol. This labelled amplified RNA (aRNA) was hybridized
to Illumina Genome-Wide Expression BeadChips (Human Ref-
6 v.3.0, Illumina, CA, USA) representing ,43,000 human
transcripts at 58uC overnight. Arrays were incubated with Cy3
streptavidin and washed according to the manufacturer’s protocol.
The chip was scanned using Illumina scanner (iScan) and the
analysis of the microarray data was done using Illumina
Beadstudio 2.0 software. The data was average normalized and
the genes which crossed the threshold of detection p value # 0.05
among all the samples and differential score p value # 0.05 among
the test samples were considered to be differentially expressed
genes. The work-flow diagram of this experiment is given in Figure
S1. The data obtained has been deposited in NCBI’s Gene
Expression Omnibus [21] and is accessible through Gene Ex-
pression Omnibus (GEO) Series accession number GSE25942
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25942).
Ingenuity pathway analysis (IPA)
Datasets representing genes with altered expression profile
derived from microarray analyses were imported into the
Ingenuity Pathway Analysis Tool (IPA Tool; IngenuityHSystems,
Redwood City, CA, USA; http://www.ingenuity.com). In IPA,
differentially expressed genes are mapped to genetic networks
available in the Ingenuity database and then ranked by score.
The basis of the IPA program consists of the Ingenuity Pathway
Knowledge Base (IPKB) which is derived from known functions
and interactions of genes published in the literature. Thus, the IPA
Tool allows the identification of biological networks, global
functions and functional pathways of a particular dataset. The
program also gives the significance value of the genes, the other
genes with which it interacts, and how the products of the genes
directly or indirectly act on each other, including those not
involved in the microarray analysis. The networks created are
ranked depending on the number of significantly expressed genes
they contain and also list diseases that were most significant. A
network is a graphical representation of the molecular relation-
ships between molecules. Molecules are represented as nodes, and
the biological relationship between two nodes is represented as an
edge (line). All edges are supported by at least 1 reference from the
literature, from a textbook, or from canonical information stored
in the Ingenuity Pathways Knowledge Base. The intensity of the
node color indicates the degree of up- (red) or down- (green)
regulation. Nodes are displayed using various shapes that
represent the functional class of the gene product.
STAT6 Silencing Increases Cholesterol Levels
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The PANTHER (Protein ANalysis THrough Evolutionary
Relationships) Classification System is a unique resource that
classifies genes by their functions, using published scientific
experimental evidence and evolutionary relationships to predict
function even in the absence of direct experimental evidence [22].
The differentially expressed genes obtained after STAT6 silencing
in NCI-H460 cells were imported into PANTHER (http://www.
pantherdb.org/), where the number of genes in each pathway
were compared against the number of genes from NCBI’s Homo
sapiens genome in that pathway. The binomial test was used to
statistically determine overrepresentation of PANTHER classifi-
cation categories. Bonferroni-corrected p values , 0.05 were
considered significant.
Cholesterol assay
Cholesterol content was determined in the cells using cholesterol
quantitation kit (Biovision, CA, USA) according to the manufac-
turer’s instruction. In brief, 10
6 cells were lysed and lipids were
extracted by homogenization with 200 ml of chloroform: isopro-
panol: Triton X-100 (7:11:0.1). These lipid extracts were vacuum
dried for 30 min and the residues were dissolved in 200 ml
cholesterol Reaction Buffer provided with the kit. Cholesterol was
estimated by spectrophotometry at l=570 nm in a 96 well plate
according to the manufacturer’s instructions. The cholesterol
levels were normalized to amounts of total cellular protein.
Promoter Analysis
To identify the common regulatory controls among the altered
genes, genes of the cholesterol biosynthesis pathway (HMGCR- 3-
hydroxy-3-methylglutaryl-Coenzyme A reductase, HMGCS1- 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase 1 and IDI1-
Isopentenyl-diphosphate delta isomerase 1) were taken for
promoter analysis. Ensembl [23] was used to retrieve 5.0 kb
upstream regions from the transcription start sites of these genes
and the transcription factor(s) binding within this region was
determined using Over-represented Transcription Factor Binding
Site Prediction (OTFBS) tool [24] that detects over-represented
motifs of known transcription factors for a set of genes.
Electrophoretic Mobility Shift Assay (EMSA)
The electrophoretic mobility shift assay was carried out as
described by Shiraga et al. [37]. Nuclear extracts were prepared
from untransfected, siRNA-transfected (60 nM, 48 h/72 h) and
scrambled siRNA transfected NCI-H460 cells by using NE-PER
Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce)
according to the manufacturer’s protocol.
The oligonucleotide sequences used in EMSA were taken from
an earlier published study [25]. Double stranded DNA was
generated by mixing equimolar amounts of the complementary
oligonucleotides in annealing buffer (Ambion, CA, USA). Mutated
sequence of the transcription factor was also used to check the
specificity of the binding of the transcription factor. These
annealed double stranded DNA were labeled with [c32-P]-ATP
(BRIT, Hyderabad, India) in the presence of T4-polynucleotide-
kinase (New England Biolabs, MA, USA) according to manufac-
turer’s instructions. Nuclear extracts (18 mg) from the untrans-
fected and siRNA-transfected cells were incubated for 30 min at
room temperature in the presence of reaction buffer containing
8 mM Tris-KCl (pH 8.0), 2 mM EDTA, 1 mM DTT, 12%
glycerol, 1 mg BSA and 1 mg of poly(dI-dC). Either the wild type
or mutated labeled double stranded oligonucleotide (40,000 cpm)
was then added to the reaction mixture and incubated for 45 min
at room temperature. On termination of incubation, samples were
loaded onto a non-reducing 6% polyacrylamide gel and
electrophoresed in 0.5X TBE. Gels were then dried and subjected
to phosphorimager analyses (FLA 2000, Fujifilm, Japan). The
densitometric analyses were done using the AlphaImager 3400
(Alpha InnoTech Corporation, San Leandro, California). The
same size rectangle box was drawn surrounding each band and the
intensity of each was analyzed by the program after subtraction of
the background intensity.
Annexin-V assay
Apoptosis was assessed by the Guava Nexin kit and the Guava
PCA system (Guava Technologies, Hayward, CA, USA). The
exposure of phosphatidyl serine (PS) on the cell surface (associated
with the onset of apoptosis) forms the basis of the Guava Nexin
assay. The Guava Nexin assay utilizes two stains (annexin V and
7-amino actinomycin D [7-AAD]). Annexin V-PE binds to PS on
the cell surface of apoptotic cells and 7-AAD, the cell impermeant
dye is an indicator of membrane structural integrity. 7-AAD is
excluded from live, healthy and early apoptotic cells, but
permeates late stage apoptotic and dead cells. The assay was
performed according to the manufacturer’s protocol and Annexin-
PE fluorescence was analyzed with the help of cytosoft software
(Guava Technologies, Hayward, CA, USA). A minimum of 2,000
events were counted.
Cell cycle assay
For analysis of cell cycle distribution, cells were fixed with ice-
cold 70% ethanol and treated with 1mg/ml RNase for 30 minutes
at 37uC. The cells were then treated with fluorescence dye
propidium iodide (50 mg/ml, Sigma, USA) which bind to DNA by
intercalating between the bases at 4uC for 30 minutes and
analyzed using flow cytometer (Guava Technologies, Hayward,
California, USA). A minimum of 5,000 events were counted.
Results
STAT6 downregulation using STAT6 specific siRNA
The efficacy of STAT6 specific siRNA to down regulate
STAT6 expression in NCI-H460 cells was evaluated by real time
PCR for RNA expression and western blotting for protein levels.
As shown in Fig. 1b, the RNA levels decreased by 1.20 fold at 24h,
2.12 fold (p value=0.046) at 48 h and by 1.66 fold (p value =
0.05) at 72 h in siRNA transfected NCI-H460 cells in comparison
to untransfected NCI-H460 cells. There was no significant change
in the untransfected cells and scrambled siRNA transfected cells at
different time points. However, the protein levels of STAT6 were
reduced in a time-dependent manner. As shown in Fig. 1a and 1b,
there was 1.12 fold decrease at 24 h, 1.79 fold (p value = 0.02)
decrease at 48 h and 2.40 fold (p value = 0.028) decrease at 72 h
post transfection of STAT6 specific siRNA in NCI-H460 cells in
comparison to untransfected NCI-H460 cells at respective time
points. We next checked the expression of phosphorylated STAT6
(pSTAT6) protein which is the activated signaling form of STAT6.
In concordance with STAT6 protein levels, the expression of
pSTAT6 protein levels was also reduced in a time-dependent
manner. There was 1.13 fold decrease at 24 h, 1.85 fold (p value
= 0.0008) decrease at 48 h and 2.67 fold (p value = 0.001)
decrease at 72 h post transfection of STAT6 specific siRNA in
NCI-H460 cells when compared with untransfected NCI-H460
cells at respective time points (Fig. 1a and b). Non significant
changes were observed in cells transfected with scrambled siRNA
(negative control) at different time points.
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line using Illumina microarray
The gene expression profiles in untransfected NCI-H460 cells
and NCI-H460 cells transfected with STAT6 siRNA were
determined by illumina microarray using two biological replicates.
Illumina array experiment identified 273 differentially expressed
genes (187 downregulated and 86 upregulated). Raw data was analysed
using Beadstudio 2.0 software. The array data was average
normalized and filtered by detection of a p value # 0.05 and
differential p value # 0.05. The list of differentially expressed
genes along with their fold changes is provided in the Table S2.
Elucidation of pathways and interactions among
differentially expressed genes
To investigate possible biological interactions of differently
regulated genes, datasets representing genes with altered expres-
sion profile derived from microarray analyses were imported into
the Ingenuity Pathway Analysis Tool.
The list of differentially expressed genes analyzed by IPA
revealed 20 significant networks (Table S3). Fig. 2a represents the
list of top 5 networks identified by IPA. Of these networks, Gene
expression, Cell death, Lipid metabolism was the highest rated network
with 28 focus molecules and the significance score of 54 (Fig. 2b).
The score is the probability that a collection of genes equal to or
greater than the number in a network could be achieved by chance
alone. A score of 3 indicates a 1/1000 chance that the focus genes
are in a network not due to random chance. The list of genes in
this network with their respective fold changes in the array data is
provided in the Table S4.
The IPA analysis also groups the differentially expressed genes
into biological mechanisms that are related to toxicity groups. In
the toxicology list, Cholesterol biosynthesis and p53 Signaling came out
to be the top two most significant pathways with a p value of 0.011
Figure1.SilencingofSTAT6in NCI-H460cells usingSTAT6specificsiRNA.a) The westernblot of STAT6 and phosphorylated form ofSTAT6 (pSTAT6)
protein on cell extracts from untransfected, STAT6 specific siRNA and scrambled siRNA transfected NCI-H460 cells at different time points as indicated. b) Graph
represents the fold change in STAT6 mRNA level, STAT6 protein and pSTAT6 protein level compared to untransfected NCI-H460 cells at respective time points.
Scrambled siRNA at different time points was used as a negative control. GAPDH was used as a loading control for densitometric analysis for western blot
analysis. The mRNA levels were normalized to 18s rRNA expression in Real time PCR analysis. The data is expressed as the mean 6 S.D. of 3 independent
experiments. * indicates p value , 0.05 in comparison to untransfected cells. ** indicates p value , 0.01 in comparison to untransfected cells. c).
doi:10.1371/journal.pone.0028509.g001
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tox list are also given in the Table S5.
Simultaneously, differentially expressed gene list obtained after
STAT6 silencing in NCI-H460 cells was fed into the PANTHER
web resource to reveal enriched pathways. Interestingly, in this
analysis too we found cholesterol biosynthesis and apoptosis sig-
naling among the significantly enriched pathways. The pathways
which passed the threshold of p value , 0.05 in PANTHER
analysis are listed in Table 1.
STAT6 silencing increases expression of genes associated
with cholesterol biosynthesis/homeostasis and enhances
cholesterol levels
Since the top most network obtained in IPA analysis was Gene
expression, Cell death, Lipid metabolism and cholesterol biosynthesis
came out enriched in both IPA and PANTHER analysis we
checked the changes in cholesterol levels after STAT6 silencing by
siRNA in NCI-H460 cells. Scrambled siRNA was used as a
negative control. Fig. 3a shows that the STAT6 silencing increased
cholesterol levels in a time dependent manner, with 1.23 fold
increase at 24 h, 1.8 fold (p value = 0.005) increase at 48 h and
2.3 fold (p value = 0.004) increase at 72 h post transfection of
siRNA in NCI-H460 cells. However, no such change was
observed in the cholesterol levels in NCI-H460 cells transfected
with scrambled siRNA. We also obtained similar results in A549
cells (Fig. 3a). There was 1.28 fold increase at 24 h, 1.6 fold
increase (p value = 0.03) at 48 h and 2.2 fold increase (p value =
0.04) at 72 h post transfection of siRNA in A549 cells, thereby
indicating that the increase in cholesterol levels could be a general
effect of STAT6 silencing on lung cells.
Since IL-4 is known to phosphorylate STAT6, we wanted to
look for the role of IL-4 in cholesterol synthesis. In NCI-H460
cells, there was 1.48 fold (p value = 0.01) change in the level of
pSTAT6 (phosphorylated form of STAT6) protein after IL-4
treatment, 0.48 fold (p value = 0.01) change after transfection of
STAT6 siRNA and 0.69 fold (p value = 0.05) change when the
cells transfected with STAT6 siRNA were treated with IL-4
(Fig. 3b). Corresponding to this, there was 0.8 fold (p value =
0.05) change in the cholesterol levels after IL-4 treatment, 1.5 fold
(p value = 0.01) change after transfection of STAT6 siRNA and
1.32 fold (p value = 0.03) change when the cells transfected with
STAT6 siRNA were treated with IL-4 (Fig. 3d). Similar results
were also observed in A549 cell line (Fig. 3d).
We next looked for the differentially expressed genes associated
with cholesterol biosynthesis/homeostasis obtained from the
microarray data. In concordance with the illumina array data,
the transcript levels of these genes were confirmed to be
upregulated by real time PCR. We observed 1.27 fold (p value
= 0.03) increase in HMGCR levels, which is the key regulatory
enzyme of cholesterol biosynthesis pathway. We also observed
1.94 fold (p value = 0.03) increase in HMGCS1, 2.7 fold increase
in IDI1, 4.2 fold (p value = 0.04) increase in CYP27B1 (Cytochrome
P450, family 27, subfamily B, polypeptide 1), and 3.0 fold increase in
INSIG1 (Insulin induced gene 1) levels at 48 h post transfection of
NCI-H460 cells with STAT6 specific siRNA in comparison to the
untransfected NCI-H460 cells (Fig. 3c).
Figure 2. Ingenuity Pathways Analysis (IPA) summary. To investigate possible interactions of differently regulated genes, datasets
representing 273 genes with altered expression profile obtained from the illumina microarray were imported into the Ingenuity Pathway Analysis
Tool and the following data is illustrated: a) The list of top five networks with their respective scores obtained from IPA b) Most highly rated network
in IPA analysis The network representation of the most highly rated network (Gene Expression, Cell Death, Lipid Metabolism). The genes that are
shaded were determined to be significant from the statistical analysis. The genes shaded red are upregulated and those that are green are
downregulated. The intensity of the shading shows to what degree each gene was up or downregulated. A solid line represents a direct interaction
between the two gene products and a dotted line means there is an indirect interaction. The genes marked with blue asterisk have been validated by
real time PCR. Genes associated with Gene expression, Cell Death and Lipid Metabolism are circled with orange, blue and purple colours, respectively.
c) Toxicology pathway list in IPA analysis. The x-axis represents the top toxicology functions as calculated by IPA based on differentially expressed
genes are highlighted and the y-axis represents the ratio of number of genes from the dataset that map to the pathway and the number of all known
genes ascribed to the pathway. The yellow line represents the threshold of p value , 0.05 as calculated by Fischer’s test.
doi:10.1371/journal.pone.0028509.g002
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observed in another lung cancer cell line, A549 (Fig. 3c) where we
observed 1.6 fold (p value = 0.03) increase in HMGCR levels, 1.4
fold increase in HMGCS1, 1.56 fold increase in IDI1, 2.4 fold
increase in CYP27B1, and 1.25 fold increase in INSIG1 levels at
48 h post transfection of A549 cells with STAT6 specific siRNA in
comparison to the untransfected A549 cells. This implies that the
effects of STAT6 silencing are general and not restricted to any
particular lung cancer cell line.
The protein levels of HMGCR, HMGCS1 and IDI1 were also
examined in untransfected and siRNA transfected NCI-H460 cells
at 48h and 72h post transfection. There were 2.9, 3.5 (p value =
0.048) and 4.3 fold increase in HMGCS1 levels, 0.94, 1.8 and 2.4
(p value = 0.03) fold increase in HMGCR levels, 1.6, 2.4 and 2.5
(p value = 0.024) fold increase in IDI1 levels at 24 h, 48 h and
72 h post transfection, respectively Non significant changes were
observed in case of cells transfected with scrambled siRNA
(Fig. 3e).
Promoter analysis and validation of Candidate
Transcription Factors
We next performed the promoter analysis for the 3 enzymes
(HMGCR, HMGCS1, IDI1) of the cholesterol biosynthesis pathway
(Fig. 4a) that are upregulated after STAT6 silencing using the
OTFBS, a tool that predicts common transcription factors for a set
of genes. This was reasonable as genes with similar functions or
that participate in a common process are often transcriptionally
coregulated [26,27]. This analysis revealed FOXD3 and FOXJ2
as the significant potential transcription factors consistently
occurring in the promoters of HMGCR, HMGCS1 and IDI1.
The binding sites of FOXJ2 and FOXD3 to the 5kB region
upstream of transcription start site of these genes as revealed by
OTFBS have been shown in Fig. 4b. To validate these
transcription factors, electrophoretic mobility shift assay was
performed for one of the candidate transcription factors, FOXJ2.
As seen from Fig. 4c, when FOXJ2 oligonucleotides were
incubated with the nuclear extract of the untransfected NCI-
H460 cells, there was considerable formation of the DNA-protein
complex in comparison to the free labeled probe. This complex
formation increased significantly in case of nuclear extracts from
siRNA transfected NCI-H460 cells and this increase was 2.07 fold
at 48 h and 2.17 fold at 72 h post transfection of STAT6 specific
siRNA indicating that STAT6 silencing increased the binding of
FOXJ2 to their binding elements that validate our predicted
finding detailed above.
Effect of STAT6 silencing in NCI-H460 cells on apoptosis
and cell cycle
Some previous reports have shown the involvement of STAT6
in apoptosis and cell cycle kinetics in different cell types [4,18,19].
Since in our study too, Gene expression, cell death, Lipid metabolism
emerged as the most significant network in IPA analysis and
apoptosis signalling pathway as one of the significantly enriched
pathways in PANTHER analysis, we thus made an attempt to
investigate whether silencing of STAT6 in NCI-H460 has any
effect on apoptosis and cell cycle progression. The annexin assay
carried out to quantify the number of apoptotic cells (Fig. 5a)
revealed that there was a time-dependent increase in annexin V
positive cells upon STAT6 silencing in NCI-H460 cells. The
percentage of annexin V positive cells increased from 4.5% in
untransfected NCI-H460 cells to 5.6% at 24 h, 11.5% (p value =
0.05) at 48 h and 23.7% (p value = 0.006) at 72 h post
transfection of NCI-H460 cells with STAT6 specific siRNA. We
also did the annexin assay in A549 cells but we did not observe any
significant changes in the annexin positive cells after STAT6
silencing (Figure S2).We also investigated the changes in cell cycle
distribution using Guava flow cytometer. As shown in Fig. 5b,
downregulation of STAT6 in NCI-H460 cells caused no
significant change in the distribution of population of cells in
different phases of cell cycle.
The most significant network in the IPA analysis revealed genes
like ATF5 (Activating transcription factor 5), BCL2L1 (BCL2-like 1),
NUAK2 (NUAK family, SNF1-like kinase, 2) and TRIB3 (Tribbles
homolog 3) which are directly or indirectly related to apoptosis. Our
Real Time data showed that ATF5, BCL2L1, NUAK2 and
TRIB3 decreased to 0.32, 0.57, 0.87 and 0.23 fold, respectively in
siRNA transfected NCI-H460 cells in comparison to untransfected
NCI-H460 cells (Fig. 5c). Simultaneously, we also checked for the
change in expression of some pro-apoptotic and anti-apoptotic
proteins by western blotting (Fig. 5d). We observed 0.85, 0.80 (p
Table 1. Enriched pathways from PANTHER analysis
a.
Pathways Homo sapiens genes (reference) Differentially expressed gene list
## expected +/- p value
Cholesterol biosynthesis 13 3 0.16 + 5.71E-04
Serine glycine biosynthesis 5 2 0.06 + 1.75E-03
Apoptosis signaling pathway 123 6 1.49 + 4.15E-03
Oxytocin receptor mediated signaling pathway 60 4 0.73 + 6.42E-03
Thyrotropin-releasing hormone receptor signaling pathway 62 4 0.75 + 7.19E-03
Cytoskeletal regulation by Rho GTPase 98 5 1.19 + 7.22E-03
5HT2 type receptor mediated signaling pathway 69 4 0.84 + 1.03E-02
Cysteine biosynthesis 1 1 0.01 + 1.20E-02
Histamine H1 receptor mediated signaling pathway 47 3 0.57 + 2.00E-02
Lipoate_biosynthesis 2 1 0.02 + 2.39E-02
Proline biosynthesis 4 1 0.05 + 4.73E-02
(
a # - number of genes, expected - the number of genes expected in the list for this PANTHER category, based on the reference list, +/- - Over representation of a
category is denoted by a + sign and under representation by a – sign).
doi:10.1371/journal.pone.0028509.t001
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levels, 0.96, 0.83 (p value = 0.023) and 0.80 (p value = 0.04)
change in BCL-xL levels and there was slight increase in BAX
(BCL2-associated X protein) levels with a fold change of 1.0, 1.37 (p
value = 0.05) and 1.1 at 24 h, 48 h and 72 h post siRNA
transfection in NCI-H460 cells, respectively.
Additionally, we found that there was 0.87, 1.38 (p value =
0.032) and 1.11 fold change in total TP53 (Tumor protein p53)
levels, 1.2, 1.4 (p value = 0.034) and 1.5 (p value = 0.048)
fold change in p-p53 (phosphorylated p53) levels, and 1.2, 1.3
(p value = 0.05) and 1.6 fold (p value = 0.046) change in
PUMA (p53 upregulated modulator of apoptosis) levels upon STAT6
Figure 3. Role of STAT6 in cholesterol biosynthesis. The total cholesterol levels after STAT6 knockdown was checked at different time points in
NCI-H460 and A549 cells. Scrambled siRNA was used as negative control. The data is expressed as the mean 6 S.D. of 3 independent experiments
performed in triplicates. * indicates p value , 0.05 in comparison to untransfected cells. a) Western blot analysis was done to analyze the change in
expression of pSTAT6 protein upon IL-4 treatment in NCI-H460 cells. GAPDH was used as a loading control for densitometric analysis. Graph
represents the fold change in protein expression compared to untransfected NCI-H460 cells. The data is expressed as the mean 6 S.D. of 3
independent experiments. * indicates p value , 0.05 in comparison to untransfected cells. b) Real Time PCR was performed to determine the changes
in expression level of genes related to cholesterol biosynthesis and homeostasis in NCI-H460 cells and A549 cells 48h post transfection of STAT6
specific siRNA. The samples were normalized to 18s rRNA expression. The real time data is expressed as the mean 6 S.D. of 3 independent
experiments performed in triplicates. * indicates p value , 0.05 in comparison to untransfected cells. c) Cholesterol assay was carried out to
determine the effect of IL-4 treatment on total cholesterol levels in untransfected and siRNA transfected NCI-H460 cells and A549 cells. The data is
expressed as the mean 6 S.D. of 3 independent experiments performed in triplicates. * indicates p value , 0.05 in comparison to untransfected
cells. d) The western blot of HMGCS1, HMGCR and IDI1 was done on cell extracts from untransfected and siRNA transfected NCI-H460 cells at
different time points. GAPDH was used as a loading control for densitometric analysis. Graph represents the fold change in protein expression
compared to untransfected NCI-H460 cells. The data is expressed as the mean 6 S.D. of 3 independent experiments. * indicates p value , 0.05 in
comparison to untransfected cells.
doi:10.1371/journal.pone.0028509.g003
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(Fig. 5d).
Discussion
Signal transducer and activator of transcription-6 (STAT6) is a
member of the STAT family of latent transcription factor and has
been found to be overexpressed in various types of cancer like
prostate and colon cancer [3,28] http://www.ncbi.nlm.nih.gov/
pubmed/18294957?dopt=AbstractPlus&holding=f1000,f1000m,
isrctn. Several studies in the literature showed that down-
regulation of STAT6 using siRNA leads to the induction of
apoptosis [4,29] but the underlying mechanism of STAT6
mediated signaling is not clear. To gain an understanding of
the biological alterations we investigated the transcriptome before
and after STAT6 silencing in NCI-H460 cells using illumina
microarray.
Gene expression profiling and network analysis by IPA and
PANTHER revealed Gene expression, Cell death and Lipid metabolism to
be most favoured after STAT6-siRNA treatment in NCI-H460
cells. An important observation in the current study was the
finding of cholesterol biosynthesis and p53 signalling in the
toxicology list during IPA analysis. We observed significant
increase in the cholesterol levels in NCI-H460 cells and in A549
cells as a result of STAT6 silencing (Fig. 3a). Our data also showed
significant increase in the level of HMGCR, HMGCS1 and IDI1
(cholesterol synthesis) and INSIG1, and CYP27B1 (cholesterol
homeostasis) genes at both transcriptional (real time PCR) and
translational levels (western blot analysis). In this study for the first
time we report that siRNA mediated silencing of STAT6 leads to
Figure 4. Schematic showing STAT6 silencing effects on cholesterol biosynthesis and validation of FOXJ2 binding by EMSA. a) siRNA
mediated STAT6 silencing increases the cholesterol levels of the cell by enhancing the expression levels of enzymes involved in cholesterol
biosynthesis pathway. # represents the rate limiting step of the cholesterol biosynthesis pathway. b) The binding sites of FOXJ2 and FOXD3 to the
5kB region upstream of transcription start site of these genes as revealed by OTFBS. 0 bp marks the transcription start site of the gene. c) The
transcription factors common to the 3 enzymes of cholesterol biosynthesis pathway that got upregulated after STAT6 silencing were predicted by
OTFBS. * transcription factor binding validated by EMSA. 18 mg of nuclear extracts from untransfected or siRNA transfected NCI-H460 cells were
incubated with wild type labeled oligonucleotide containing the binding elements of FOXJ2. Mutated probe was used to check the specificity of the
DNA-protein complexes. On termination of incubation, samples were resolved in a non-denaturing polyarylamide gel and subjected to
phosphorimager analysis. Lane 1: labeled FOXJ2 specific oligos, lane 2: untransfected NCI-H460 cells incubated with labeled FOXJ2 specific oligos,
lane 3: NCI-H460 cells tranfected with STAT6 specific siRNA at 48 h incubated with labeled FOXJ2 specific oligos, lane 4: NCI-H460 cells tranfected with
STAT6 specific siRNA at 72 h incubated with labeled FOXJ2 specific oligos, lane 5: NCI-H460 cells tranfected with scrambled siRNA incubated with
labeled FOXJ2 specific oligos, lane 6: untransfected NCI-H460 cells incubated with labeled mutated FOXJ2 specific oligos.
doi:10.1371/journal.pone.0028509.g004
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biosynthesis/homeostasis resulting in enhanced cholesterol levels
in the cells. Till date, there are only a few reports where indirect
links between STAT6 and cholesterol biosynthesis have been
observed. King et al in their study reported that IL-4 deficiency in
C57BL/6 LDL receptor (LDLr)-/- mice promotes gallstone
formation which maybe due to deregulation of genes involved in
cholesterol metabolism, thereby implying that IL4 might be linked
to cholesterol metabolism [30]. Black et al also observed that the
use of IL-4 lowers the blood cholesterol levels [31]. We also found
slightly decreased cholesterol levels after IL-4 treatment in our
study. Herein, we show for the first time that direct inhibition of
STAT6 can lead to an increase in cholesterol levels in lung cancer
cells.
This inverse relationship of cholesterol biosynthesis and STAT6
is further strengthened by the reports on cholesterol lowering
drugs simvastatin and atorvastatin which target HMGCR, lead to
an increase in phosphorylated STAT6 [32,33]. It is also well
established that STAT6 is important for the development of
asthma [34,35,36] and a study on US population by Fessler, et al in
Figure 5. Effect of STAT6 silencing on apoptosis and cell cycle. a) To determine whether STAT6 downregulation in NCI-H460 cells leads to
apoptosis, Annexin-V-PE binding assay was done at different time periods as described in ‘‘Materials and Methods’’ section. X-axis represents Annexin
V-PE positive cells whereas Y-axis represents 7-AAD positive cells. % here indicates the percentage of dead cells. b) Cell cycle assay was also done to
check the distribution pattern of untransfected and siRNA transfected NCI-H460 cells in different phases of cell cycle. Cells were harvested post
transfection (at different time points as indicated) and subsequently assayed for their DNA content by flow cytometry. c) Real Time PCR was done in
NCI-H460 cells to validate the genes which emerged out to be associated with apoptosis or cell death from the most significant network in the IPA
analysis. The samples were normalized to 18s rRNA expression. The real time data is expressed as the mean 6 S.D. of 3 independent experiments
performed in triplicates. * indicates p value , 0.05 in comparison to untransfected cells. d) Western blot was performed to analyze the expression of
some pro-apoptotic and anti-apoptotic proteins in untransfected and siRNA transfected NCI-H460 cells. GAPDH was used as a loading control. The
data is expressed as the mean 6 S.D. of 3 independent experiments. * indicates p value , 0.05 in comparison to untransfected cells.
doi:10.1371/journal.pone.0028509.g005
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cholesterol are inversely related to asthma [37], thereby further
pointing towards the inverse relation between STAT6 and
cholesterol.
In the present study, we not only observed inverse relationship
of STAT6 and cholesterol biosynthesis but also found several
conserved FOXJ2 and FOXD3 binding sites in the 5Kb region
upstream of HMGCR, HMGCS1 and IDI1 (genes of the
cholesterol synthesis pathway). FOXJ2 belongs to the family of
forkhead box (FOX) proteins [38] and has been validated in our
study using EMSA. [39]. Although, the structural and functional
domains of FOXJ2 have been characterized [40], very little is
known of the biological effects of FOXJ2 [41]. The enhanced
binding of FOXJ2 to the key enzymes of cholesterol biosynthesis as
a result of STAT6 silencing could have great potential in
understanding the complexities of STAT6 signaling.
Several reports in the literature suggest that STAT6 knockdown
is associated with inhibiting proliferation and enhancing apoptosis
[1,3]. Moreover, STAT6 has also been found to be activated
spontaneously in human cancers such as prostate cancer [18], B
cell lymphoma [42] and Hodgkin’s lymphoma [43] suggesting that
an active STAT6 signaling may be beneficial for cancer cell
growth. In our study, cell death and p53 signaling came out as
significantly altered upon STAT6 silencing as revealed by the IPA
analysis (Fig. 2a and c). Since, p53 is well documented to have a
role in apoptosis [44,45] we checked the expression of the genes
associated with p53 signaling such as p53, phosphorylated p53,
PUMA, BCL-2, BAX, BCL-xL by western blot analysis. We
observed increased expression of p53, phosphorylated p53, PUMA
and BAX and reduced expression of BCL-2 and BCL-xL after
STAT6 silencing. However, further study is needed to investigate
the role of p53 in STAT6 signaling. Herein, we also observed an
increase in annexin positive cells in a time dependent manner in
control and STAT6 knockdown NCI-H460 cells. Contrary to our
findings, an earlier study has shown that STAT6 induces apoptosis
[46]. Our cell cycle analysis did not show any significant change in
the number of cells in any phase. This is in contrast to the report
by Zhang et al in 2005 where they had observed increased cells in
G1 phase after STAT6 silencing in HT-29 cells [4]. Kaplan et al in
1998 had also reported that STAT6 deficient spleen cells show G1
arrest [47].
In conclusion, the study not only validates the novel finding of
increased cholesterol levels after STAT6 silencing in NCI-H460
cells but also confirms the anti-apoptotic role played by STAT6.
Since STAT6 can act as either pro-or antiapoptotic factor
depending on the cell type a key pending question is whether
STAT6 siRNA may have therapeutic activity in cancer. Future
studies within the field of apoptosis will expand our understanding
of the complex mechanisms underlying STAT6 mediated
signalling. The knowledge of inverse relationship between STAT6
and cholesterol biosynthesis can be of significant potential in
understanding and designing therapeutics for several pathological
conditions where STAT6/cholesterol is implicated.
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